From: Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients
All (n = 131) | Hemopathy (n = 58) | Solid tumors (n = 29) | Endocrinopathies (n = 16) | Other (n = 28) | |
---|---|---|---|---|---|
Hyperhydration, n (%) | 124 (94.6) | 53 (91.3) | 29 (100) | 16 (100) | 26 (92.8) |
Crystalloid, n (%) | 119 (90) | 50 (87.7) | 29 (100) | 16 (100) | 24 (85.7) |
Volume at day 1 (L/day) | 3 [2, 3] | 3 [2, 3] | 3 [2.5; 3] | 3.25 [2.25; 4] | 2 [2, 3] |
Side effect: pulmonary edema, n (%) | 11 (8.3) | 9 (17) | 2 (6.8) | 0 | 0 |
Bisphosphonate infusion, n (%) | 103 (78.6) | 49 (84) | 26 (89.6) | 12 (75) | 17 (60.7) |
Second infusion, n (%) | 13 (10) | 5 (10.2) | 5 (19.2) | 0 | 3 (10.7) |
Corticosteroids, n (%) | 65 (50) | 49 (84.4) | 10 (34.5) | 0 | 6 (21.4) |
Furosemide, n (%) | 13 (10) | 6 (10.3) | 1 (3.4) | 0 | 6 (21.4) |
Calcimimetics, n (%) | 6 (5) | 0 | 1 (3.4) | 5 (31) | 0 |
Calcitonin, n (%) | 12 (9) | 4 (6.8) | 5 (17.2) | 1 (6.3) | 2 (7.1) |
Renal replacement therapy, n (%) | 25 (19) | 20 (34.4) | 3 (10.3) | 1 (6.3) | 1 (3.6) |
Duration of RRT (d) | 5 [2.5; 7] | 5 [2.5; 6] | 3 | 3 | 11 |
Vasopressor, n (%) | 6 (4.5) | 5 (8.6) | 0 | 0 | 1 (3.5) |
Mechanical ventilation, n (%) | 10 (7.6) | 6 (10.3) | 3 (10.3) | 0 | 1 (3.5) |
ICU mortality, n (%) | 13 (9.9) | 4 (6.8) | 6 (20.6) | 1 (6.3) | 2 (7.1) |
Hospital mortality, n %) | 26 (21.3) | 10 (17.2) | 13 (44.8) | 1 (6.3) | 2 (7.1) |